论文部分内容阅读
目的:观察米非司酮治疗皮下埋植避孕所致子宫异常出血的临床效果。方法:观察组患者采取口服米非司酮片进行治疗,对照组则采取口服炔雌醇片加以治疗,对比两组患者的临床疗效和不良反应。结果:两组患者服药前3个月、服药期间3个月的出血天数和出血次数,差异均不具有显著性(P>0.05)。两组患者服药后3个月的出血天数和出血次数,差异均有显著性(P<0.05),且观察组明显优于对照组。观察组不良反应发生率为54.16%,对照组不良反应发生率为54.16%,两组不良反应发生率差异具有显著性(P<0.05)。结论:米非司酮是治疗皮下埋植避孕所致子宫异常出血的一种有效方法,临床效果显著,而且不良反应均较轻微,值得进一步推广应用。
Objective: To observe the clinical effect of mifepristone in treatment of abnormal uterine bleeding caused by subcutaneous implantation of contraception. Methods: Patients in the observation group were treated with oral mifepristone, while those in the control group were treated with ethinyl estradiol tablets. The clinical efficacy and adverse reactions of the two groups were compared. Results: There was no significant difference in the days of bleeding and the number of hemorrhage between the two groups in the three months before taking the drug and in the three months before taking the drug (P> 0.05). The bleeding days and the number of bleeding in the three months after taking the two groups were significantly different (P <0.05), and the observation group was significantly better than the control group. The incidence of adverse reactions in the observation group was 54.16%, and the incidence of adverse reactions in the control group was 54.16%. There was a significant difference in the incidence of adverse reactions between the two groups (P <0.05). Conclusion: Mifepristone is an effective method for the treatment of abnormal uterine bleeding caused by subcutaneous implantation of contraceptives. The clinical effect is significant and the adverse reactions are mild, which is worth further promotion and application.